NCT04763616View on ClinicalTrials.gov

Study of Isatuximab and Cemiplimab in Relapsed or Refractory Natural Killer/T-cell Lymphoid Malignancy

PHASE2RecruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 25, 2021

Primary Completion Date

April 30, 2023

Study Completion Date

April 30, 2026

Conditions
Natural Killer/T-cell LymphomaRelapsed Natural Killer/T-cell LymphomaRefractory Natural Killer/T-cell Lymphoma
Interventions
DRUG

Isatuximab

The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.

DRUG

Cemiplimab

The treatment cycle will be repeated up to 2 years. If a patient shows disease progression or unacceptable toxicity, the study treatment will be discontinued and followed up for efficacy and safety after the discontinuation of study treatment.

Trial Locations (1)

06351

RECRUITING

Samsung Medical Center, Seoul

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

Won Seog Kim

OTHER